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congestive heart failures t 
class HV congestive heart 
patients who receive a heart 
? mortality rate of <5%, a 
I-year survival rate approaching 85% and survival rates of 
75% to 80% 5 years after transplantation (see Task Force 4). 
Not only is qtantity of life prolonged, but qjuahty of life is 
markedly ~m~rovcd~ as wiil be p ented in the next section 
of this report. The success Q art tra~spla~tat~o~ has 
resuhed in a critical imitation of donor supply, e 
increasing numbers of new t 
ethesda Conference (6) in 1968 
the promise and the resultant ethicai diiemmas ibat cardA= 
ogists now confront. 
Each year approximately 40, pIersons 
from conditions for which he transpla 
tient-specific considerations pre- 
y of these persons. the demand 
es to increase. However. donor 
supply remains unchanged ata t 2,000 annually. Thus, far 
fewer patients receive atransp than could benefit. Twice 
as many patients are currently listed for heart rauspia~ta- 
tion as will undergo transplantation this year. This limited 
availability of donor organs raises many clinical and ethical 
issues about he process of patient selection and allocation. 
Recipient criteria can vary from center to center, but at- 
tempts should be made to ensure consistency in clinical 
evaluation and objective assessment of maximal benefit to be 
obtained. Assessment ofcandidates for transplantation who 
are already dependent on mechanical orparenteral isotropic 
support is simply a process by which known contraindica- 
tions to transplantation are systematica!!y excluded. ith 
the increased acceptance of heart ransplantation as a viable 
treatment modality, mauy patients are understandably re-
ferred earlier in the course of their disease and may be 
judged not to need transplantation for short-term survival 
of all these issues. 
are subjective ciinical ~~se~at~o~s 
vular heart disease or congenital heart disease are also 
sometimes suitable candidates. Patients with hype~rophic 
cardiom active myoc 
osis and unresectable 
successful transplantation, altho 
osis or sarcoidosis may limit t 
procedure (12), and patients 
have a less favorable outcome after transplantation (13). 
Refractory angina in patients who have undergone r peated 
revascularization proccdd a RS is an emerging new indication: 
tra~s~~a~tat~o~ has been consi 
than high risk revasc~~a~zatio~ p 
ment and, hence, is recommended to some patients rather 
than more conventional surgical interventions. 
Several well established co-morbid conlditions in potential 
recipients have traditionally served as secondary exclusion 
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Table 1. Secondary Exclusion Criteria for Heart Transplantation 
Coexistent systemic illness with poor prognosis 
irreversible pulmonary parenchymal disease 
Irreversible renal dysfunction with serum creatinine >2 mg!dl or creatinine 
clearance 60 mUmin 
Irreversible hegatic dysiunction 
Severe peripheral and cerebrovascular obstructive disease 
Insulin-dependent diabetes with end-organ damage 
Active infection 
Coexisting neoplasm 
Pulmonary hypertension with irreversibly high pulmonary vascular 
resistance cpulmonary vascular resistance >6 Wood units or 3.0 Wood 
units after treatment with vasodilators) 
Acute pulmonary embolism or infarction 
Active diverticutosis or diverticulitis 
Active peptic ulcer disease 
Myocardial infiltrative and inflammatory diseases 
Severe obesity 
Severe osteoporosis 
Psychosocial instability or substance abuse, or both 
criteria (Table I) and need to be carefully excCuded or 
evaluated uring routine screening (Table 2). Active sub- 
stance abuse is believed to define a patient group that will do 
poorly after heart transplantation (14,W. On the basis of 
some clinical experience, patients with congestive heart 
failure due to anthracycline cardiotoxicity who are believed 
to have been cured of malignanWj -XI by conventional clinical 
criteria may be considered for cardiac transplant. Clinically 
significant cerebral or peripheral vascular disease should be 
reason for exclusion when its presence limits rehabilitation. 
Experience in some centers has challenged many of the 
listed secondary exclusion criteria for heart ransplantation. 
Diabetic patients without severe secondary end-organ dis . 
ease (retinopathy, neuropathy ornephropathy) have under- 
gone transplantation successfully with excellent intermedi- 
ate results (16). Patients with refractory endocarditis have 
likewise undergone successful transplantation without recur- 
rent infection (17). Current surgical skills and immunosup- 
pressive strategies now permit combined transplantations i  
some centers for patients with previous absolute contraindi- 
cations: combined kidney and heart ransplantation f r renal 
failure and heart failure, and combined liver and heart 
transplantation for familial hypercholesterolemia andend- 
stage coronary artery disease (18). Although such proce- 
dures are a testimony to surgical expertise, they also chal- 
lenge current indications and contraindications for heart 
transplantation and should only be performed as experimen- 
tal procedures and not accepted as a standard of care. 
Older age has historicaily been considered among the 
primary exclusion criteria for transplantation. Early collec- 
tive transpiant experience used the age of 55 years as an 
upper limit, but more recent experience indicates that highly 
selected older patients receive the same short-term benefit as 
younger patients (19). It has been proposed that recipient age 
be considered a factor in donor allocation (older donor 
hearts placed in the older recipient), but there continues to 
Table 2. Recommended Evaluation Before Transplantation 
General data 
Comprehensive history and physical examination 
Blood chemistry determinations including t,enal and liver function panels 
Complete blood count, differential, platelet count, prothrombin time. partial 
thromboplastin time, fibrinogen 
Urinalysis 
Srooi for guaiac examination X3 
24 hour collection of urine for creatinine clearance, total protein 
Nutritional sra!us and diet history 
Mammography* 
Papanicolaou smear’ 
Consultation* 
Psychiatry 
Physical therapy 
Social services 
Dental 
Pulmonary function testing* 
Lung ventilation-perfusion scanning* 
Basic cardiovascular data 
Electrocardiogram 
Chest X-ray film 
Exercise test with oxygen consumptton (peak V023 
Detailed hemodyndmic evaluation with right heart cdrdidc cdtheterizldlion 
Radionuclide ventriculogram’ 
Echocardiogram 
Left heart catheterization- 
Myocardial biopsy* 
Basic immunologic data 
Blood type and antibody screen 
Human leukocyte antigen (HLA) typing 
Panel of reactive antibodies screen 
Basic infectious disease background data 
Serology for 
Hepatitis HBsAg. HBsAh. HBcAh. C 
Herpes group virus 
Human immunodeticiency VirUs 
Cytomegalovirus (CMV) IgM and IgG amibody 
Toxoplasmosis 
Varicella and rubella titers 
EB viral capsid IgG, IgM antibodies 
Lyme titers* 
Histoplasmosis and coccidioidomycosis complement fixing antibodies 
Venereal Disease Research Laboratory and buoiescent treponemal 
antibody tests 
Urine for viral cultures (cytomegalovirus, adenovirus) 
‘PhKrat swab for viral cultures tcytomegalovirus. adenovirus. herpes 
simplex virus) 
Urine culture and sensitivity 
Stool for ova and parasites x3* 
Skin testing for purified protein derivative with control, IIIUIII~S. 
dermatophvlin, histonhdalnosis and coccidioidomvcosis 
“Only if appropriate. 
be reluctance toadd this dimension to a complicated eth;cd 
and medical dilemma. 
There is one hemodynamic exclusion criterion for ortho- 
topic cardiac transplantation. A  elevated pulmonary va~u- 
lar resistance % to 8 Wood units or a transpulmonary 
gradient >I5 m:ra Hg predicts an individual with a high risk 
of developing acute right ventricular failure in the immediate 
istance ither is r 
with such intensive 
graft loss due to nonco 
social evaluation shoul 
may require specific intervention before a 
and inadequate family support. any patients with severe 
chronic heart failure will manifest depression, for which 
evaluation is necessary to distinguish endogenous from 
exogenous despair and to identify the need for long-term 
psychiatric therapy after transplantation. Issues of psychiat- 
ric diagnoses, ocietal role and family support can be eval- 
uated primarily in the context of their impact on potential 
compliance rather than by invocation of societal norms and 
values. All impaired or disabled patients, whether the dis- 
ability limits physical or mental performance, should be 
evaluated on an individual basis in terms of their ability to 
comply with their medical regimen and to enjoy prolonged 
survival after Cran.,plantaGon, Current echniques and crite- 
ria of psychologic evaluation vary widely among heart 
transplant programs and standardized vacuations have been 
suggested but not va!idated (27-29). Ahhoug& extensive 
research needs to be dare in this area. some lessons may be 
derived from the t xperience with ktdney tra~~s~~antat~on, in 
which a pretranspiantation history of noncompliance was 
highly associated with noncompliance after transplantation 
(30), which has been shown to be the major cause of late 
graft loss for both kidneys and hearts (31). 
In pediatric patients, the naturaal history of heart failure 
syndromes i not precisely ardioi- 
ogists would agree that a c failure 
who requires inot c support should be evaiMated for 
trans~~antat~~ln, he ogression of disease 
heart failure who not yet hospital bo 
unpredictable. There is no consensus of reliable predictors 
for poor survival in dilated ~ardiomyo~atby 
in children (33.34). As in adults, significant a 
igh filling pressures have been identified as 
ors of early mortality and may serve to ide 
nefit from urgent ra 
chnicaf information on 
decision is made to p 
children with unmeasurable 
surprisingly free of symptoms and may do well for years 
until a viral illness compromises the remanning cardiac 
24 MUDGE ET AL. 
TASK FORCE 3 
JACC Vol. 22, No. 1 
July 1993: l-64 
reserve. Genera! clinical indications for referral to a trans- 
plant program include incre3sil:g congestive failure despite 
maxima! dosage of ora! diurccic agents and afterload reduc- 
tion with an angiotensin-conrrerting enzyme inhibitor. Con- 
genital heart lesions must be evaluated inthe context of their 
physi&gy; in some cases, poor ventricular function Wi!! not 
be he reason for referral for transplantation. ]For example, 
in patients with a single ventricle after pe,rformance of a 
Fontan repair. +.I mildly depressed systemic ventricular 
function in addition to an abnormality in lung perfusion 
could be responsible for low output and make transplanta- 
tion the only option for survival. Other clinical indications 
for transplant evaluation i clude growth failure or cardiac 
cachexia, even when control of symptomatic congestive 
heart failure appears adequate. 
Although most of the established exclusionary co- 
morbidities inadult recipients apply to pediatric patients, a 
few are modified and some are unique. Significant irrevers- 
ible hepatic or renal dysfunction or infection remains a 
contraindication t  transplantation. Prior strokes or seizure 
disorders are not exclusionary if the outlook for recovery of 
function is reasonable. Systemic diseases that preclude 
transplantation e compass uch disorders as degenerative 
neuromuscular diseases or neoplasia. One challenging as- 
pect of transplantation n children involves reconstruction f 
complex congenital lesions and the creative surgical ap- 
proaches that must be devised to repair them. It has been 
shown that virtually any anatomic aberration ofarterial or 
venous connection is surmountable with heart ransplanta- 
tion except when the pulmonary arteries are too small to be 
repaired; the patient with inadequate pulmonary artery di- 
ameter at the hila should not be considered a candidate for 
an orthotopic transplant, but would need heart-lung :rans- 
plantation (35,36). 
With the refinement of fetal echocardiography, there is 
now a new subset of potential patients with lethal cardiac 
anomalies who are being considered for transplantation 
while still in utero. When feasible, the delivery of the infant 
is coordinated with donor procurement. The in utero evalu- 
ation of these patients consists of accurate diagnosis, exclu- 
sion of other anatomic and medical contraindications and 
family counseling. The United Network for Organ Sharing 
WNOS) has a special category for listing these potential 
patients after 32 weeks’ gestation SD that they will not take 
precedence over neonates already listed (37). 
Another criterion unique to transplantation in children is 
the demonstration f a reliable caregiver for the dependent 
child. Intensive ducation of the family as to the IifestyIe, 
r& and complications that can accompany transplantation 
is essential. A pediatric transplant program has the ob!iga- 
ticn to seek a competent caregiver when one is not readily 
obvious. The carcgiver ideutified need not be a parent; 
however, he or she must have legal responsibility for total 
care in order to deal with the strict medical regimen required 
for these patients. This criterion is equally important for the 
adolescent patient because ofthe propensity for noncompIi- 
Table 3. Potentially Reversible Conditions Contributing to Heart 
Failure Decompensation 
Patient-specific considerations 
Recent onset of nonischemic cardiomyopathy 
Major areas of reversiiiie mjocardial ischemia 
Atrial fibrillation or other atria1 arrhythmias 
Alcohol consumption 
Endocrine disorders 
Physician- and nurse-specific considerations 
Perception of “failure of medical therapy” 
Inadequate recognition of volume overload 
Ineffective use of vasodilators and diuretic agents 
Therapy with negative inotropic drugs 
Therapy with prostaglandin inhibitors 
Lack of patient education about compliance regarding salt, fluid and 
diuretic adjustment 
ante in this age group. Another unique feature is that the 
pediatric cardiac transplant recipient pool is still small com- 
pared with the number waiting for adult donors. Some donor 
organs are discarded or used for homografts when there is no 
available r cipient for sma!!-,,, c;ved onors It is reasonab!e to 
offer transplantation a d a tower but significant chance for 
survival to these very high risk children when a dsnor heart 
cannot be used for a more suitable candidate. 
Discussions about patient selection for transplantation 
have previously focused on the contraindications rather than 
on objective indications. Before examining these objective 
indications for transplantation, there are several general 
clinical considerations that should be emphasized regarding 
the importance of the careful initial evaluation and ongoing 
reevaluation by transplant centers of patients elected for 
heart ransplantatik,*rc. 
1. Every patient, regardless of the nature and degree of 
cardiac dysfunction, deserves evaluation for the potentially 
reversible factors contributing todecompensation (Table 3). 
The intensity of this component of the evaluation varies 
considerably among transplant programs. Common factors 
limiting adequate compensation f heart failure include atria! 
fibrillation, subtherapeutic use of diuretics and vasodilators 
and incomplete patient education about how to monitor and 
control volume status. Adequate therapy may be prevented 
by lack of clinical recognition of hypervolemia, fear of 
potential hypovolemia nd concerns about the danger of 
hypoperfusion with the use of low dose converting enzyme 
inhibitor (38,39). 
2. Present extended waiting times allow for clinical Im- 
provement tooccur before transplantation; the condition of 
many patients may be stabilized on medical therapy and 
transplantation can be safely deferred (40). Frequently the 
referring physicians and patient will focus on the transplant 
process once it has been activated and may be re!uctan;t to 
consider medical therapy even if stability or improvement is 
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a consistent basis by UN transplant centers nt~~~z~ng objective 
criteria to be further discussed and if the ultimate priority of 
the deselected patient, if rehste ed by 
ere has also been ~nsnfficient emphasis on the contin- 
observation ofpatients iniiially considered not to need 
splantation atthe time of initial evahration. I  one study 
% of such patienis died within a year after eturning 
listing potential recipients do not provide an objective as- 
sessment of prognosis. Hn addition to the 2,500 pati 
currently listed for heart transplantation in the tJ.S., 
more are added each month. Only 150 will receive a trans- 
plant each in critical 
receive a t presenr aii 
they make up only 5% to 6% ot ihe total waiting list at any 
given time, Approximately 20% of candidates who are 
initiahy listed as critical will not survive to transplantation. 
In contrast, the condition of ~2 of the patients injtially 
listed as outpatients will become ica! in the 1st year after 
listing. However, >50% of patients currently listed will 
survive for an extended period outside the hospital wit 
transplantation (42). Although it is difficult o estimate can- 
didate survival without ransplantation because of the fre- 
quency of transplantation, i  one study actuarial survival 
without ransplantation n a stable group of outpatients was 
67% at I year. For those who survived 6 months on the 
waiting list, survival over the next 12 months was 83% when 
careful management was continued. For those patients who 
survive 9 months waiting for a transplant. transplantation 
does not appear to convey an additional short-term survival 
benefit over the next year (42). These patients hould prob- 
ably not continue to be listed for transplantation. All trans- 
plant programs should continuously screen waiting lists to 
ensure that the active list represents a patient group with 
maximal benefit for survival with transplantation. 
4. Given the limited donor supply, objective recipient 
criteria should be developed to maximize the benefit offered 
by heart transplantation. “his problem becomes more fo- 
cused if we evaluate patients and estimate benefits for only I 
year at a time. Patients with a poor 5-year prognosis may 
have a good prognosis for 1 year, after which they should 
again be evaluated to determine their need for transplanta- 
e next year. Conversel 
candidates for urgent rans~iantat~on did ot ch 
the current number. Outpatients wo 
12% chance of transplantation eat 
ora!ion of therr condition to req 
than limitations 0 
not restored to corn 
failure that is “stable” by clinical criteria: app 
some indications that performance of iow levei exercise 
consistent with daily activity may improve more than peak 
capacity (45). Thus, the patient who is in stable condition 
and comfortable performing routine a.ctivities. but “would 
like to do more” may not necessarily derive benefit from 
transplantation. With the limited number of donor Irearts 
available, the argument could be made that the overall 
benefit to patient candidates is maximized by maximizing 
survival rather than functional capacity, which often deteri- 
orates and improves concomitantly with expected survival. 
Moreover. heart transplantation should not replace other 
high risk surgical interventions simply because collective 
results offer a better long-term surviva:. 
6. It should be emphasized at donor organs are a 
societal and regional resource t 
fair, consistent and equitable fa 
criteria for patient eligibility are 
gram shopping” by patients with the resources to do so and 
“ca~di&te shopping’” by programs looking for the Iowest 
postoperative mortality statrstics, which may be achieved by 
performing a tr ansplant procedure in those patients who 
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need it least. The length of recipient waiting lists is also one 
of the justifications given for listing patients before severe 
decompensation, which Peads to further list expansion and 
yet longer waitiilg times. Because many patients await heart 
transplantation at home, and allocation of hearts is often 
made solely on the basis of waiting time, this subjective 
clinical criterion will not identify those persons in greatest 
need of transplantation. 
The clinical and ethical issues of retranspiantation should 
also be addressed. Care should be taken that patients do not 
feel abandoned when retranspiantation s not an option. 
Recurrent rejection and aiiograft coronai’y artery disease wiill 
inevitably ead to a finite number of graft failures in patients 
who continue to be suitable candidates for retransplantation 
without seconddry co-morbidity. The ultimate decision re- 
garding the appropriateness of retranspiantation should is- 
tinguish between retransplantation for acute histologic rejec- 
tion, which has been associated with a poor short-term 
prognosis, and retranspiantation f r allograft coronary ar- 
tery disease or chronic graft failure, which may have a 
short-term survival rate comparable tothat for initial trans- 
plantation i critically iii patients. But because the issue of 
heart retransplantation is ot unique in this era of limited 
donor supply and restrained financial resources, the entire 
transplant community must confront he many complicated 
dilemmas of retranspiantation f r all solid organs. 
Although it will not be possible to develop erfect objec- 
tive clinical criteria to identify patients who should and 
should not be placed on the transplant waiting list, the ability 
to predict survival in patients with heart failure is critical to 
optimizing the selection of transplant candidates. In early 
studies, several univariate predictors of reduced survival in 
patients with heart failure were identified (45-Q). These 
predictors included areduced left ventricular ejection frac- 
tion, New York Heart Association functional class, the 
presence ofa hhird heart sound, left ventricular conduction 
delay on a baseline ECG, reduced serum sodium, elevated 
serum catechoiamines, increased pulmonary capillary wedge 
pressure, reduced cardiac index and low peak oxygen con- 
sumption (VO& A few studies have used multivariate t ch- 
niques to predict survival but no consistent objective clinical 
criteria have emerged. These early studies may not reflect 
current medical practice, as antiarrhythmic drug use was 
more prevalent and use of angiotensin-converting enzyme 
inhibitors more sparing. MuitivGate analysis performed on 
15 variables from 1,088 patients enrolled in the recent 
PROMISE trial may be more reflective of current medical 
practices. Baseline variables that provided independent 
prognostic information were ~o~s~stai~ed ve~6~~c~~a~ tacachy- 
cardia on 24-hour ambulatory EC6 ( ok39 ~o~ito~i~g” 
New York Heart Association functiona lass, ejection frac- 
tion. serum sodium, blood urea nitrogen and a~~~a~hytbm~c 
drug use (52). 
Although ejection fraction is the best variable to 
myocardial failure, it does ne)t quantify the degre 
gestive heart failure ai-~d it cannot predict the degree of 
clinical compensation that can be ach d and maintained. 
Approximately 95% of patients who u 
have congestive heart failure with 
eject Q . .
with d 
tion to be the sole predict 
recommended hca:t tra~s~la~tat~Q~ for ali patients with an 
ejection fraction <X%, a rec~rnrne~dat~~~ that must be 
viewed with caution because the statisticai analjlsis is 
flawed, with no forme! testing of difference in survival 
between subgroups straiified by ejection fraction. The num- 
ber of such patients with a reduced ejection fraction ot only 
exceeds the number of available hearts but, if these patients 
are discharged from the hospital, they can have a l-jjear 
survival rate without ransplantation th;;t is 40% and even 
higiier in some subgroups (54). 
The (other clinical criteria for atients with more ad- 
vanced heart failure-New York eart Association func- 
tional class III or IV, history of frequent hospitalizations, 
high pul,monary artery wedge and right atrial pressures, low 
cardiac output, low serum sodium, elevated plasma norepi- 
nephrine l vels, history of syncope, symptomatic ventricular 
arrhythmias nd sudden death-all identify patients who 
need further therapy but not necessarily transplantation. 
Each of these clinical variables has usually been measured at
peak decompensation and may be of more prognostic value 
in this group if they are assessed after maximal medical 
interventions. Most important, here are no currently vaii- 
dated indexes of prognosis that are not heavily influenced by 
the adequacy of therapy immediately before evaluation. 
Once maximal therapy has been instituted and main- 
tained, peak VOZ measured during maximal exercise testing 
provides an objective assessment of functional capacity in 
patients with heart failure and an indirect assessment of
cardiovascular reserve. The value of peak VOZ in optimally 
timing heart ransplantation was studied in Ii4 consecutive 
ambulatory patients referred for heart ransplantation eval- 
uation between 1986 and 1989 (55). Patients were prospec- 
tively classified into three groups: Group I patients had pep’- 
V02 114 ml/kg per min and were accepted as transplant 
candidates; Group 2 patients had peak VO? ~714 ml/kg per 
min and transplantation was deferred; Group 3 patients had 
peak VO, 114 ml/kg per mIn but were rejected for twns- 
plantation for noncardiac reasons. Serial assessments were 
performed with crossover between Groups I and 2. The 
three groups had comparable functional class, left ventricu- 
lar ejection fraction and cardiac index. Patients with VO, 
>I4 ml/kg per min had a l-year survival rate of 94%, 
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e patients was that of sudden 
urvivai rates occurre 
with peak VO:, 510 ml/kg 
be accepted as transplant c 
n many patients wieh peak VO, >14 mVkg per 
Mation may be deferred. unless other clinical 
as symptomatic ventricuiar ~bytbm~~, intrac- 
yocardia! ischemia nd persistent 
patients at roughly 50% to 7 peak VO2 unless the rest Is 
terminated ear?y by ischemia. Though peak 110, F;S svrdes an 
indirect assessment of cardiac output and cardiac reserve. a 
variety of actors serve to li 
er, conditionin status, 
of 14 ml/kg per min 
predicted maxlrnai exercise capacity for ai; airive 60-year 
o!d man but only ?O% oftbe predicted capacity for a X-year 
old man. finis level of activity may provide an ~~acce~tab~e 
quallt:v of for a young adult. Peak ‘40, is a 
criterion t needs to be viewed in the context of 
evaluation procedure n.rrd the patient’s age. The ability to 
demonstrate an improvement in exercise capacity with med- 
y may be part~c~~ar~y ‘iavorable as an i~~~~a~i~~ of 
restored compensation that will reflect not only an improve 
prognosis. but also an improved quality of life. 
tance of peak Vo, mandates that it be measu 
and not estimated by exercise dun&on or met 
alents (56). 
Risk factors less directly related to the degree oi hemo- 
dynamic compensation have not been well studied. The 
major threat to survival in patients with preserved exer 
capacity is sudden death. Patients with chronic heart fai 
dre at greater risk for sudden death than is any other 
definable subset of patients in cardiovascu!ar medicine, but 
our ability to identify those patients with heart failure at 
greatest risk for sudden death is poor. Poor hemodynamis 
measurements and the existence of nonsustained ventricular 
tachycardia do predict total cardiac mortality but not spe:cif- 
icaiiy sudden death probability. Electrophysiologic testing. 
signal-averaged electrocardiography and autonomic profihng 
have been variably prechctive of future fatal arrhythmic 
events. More investigations are needed to identify patients 
who are at the greatest risk fcr sudden death i5ii. 
Before assessment of functional status, patients with 
heart failure should undergo aggressive therapy with combi- 
nations of vasodilators and diuretic agents. Therapy should 
be adjusted until clinical congestion has been resolved or 
-with intravenous foho~ved by oral E 
medical therapy have been thorn 
Jects. 
After detailed and e rt eva~~a~~~~, all potential re- 
cipient; can be conside in one of the three fo~~~~~~~ 
roiling ro~t~~e activity 
amenable to bypass !.urgery or a 
urWIt q m~to~t~c ventricuku- a 
tory to aii Fccepted therapeutic modalities 
11. Pr-ohrnh~~~ hdi ~ations,fov Cnrdiac ~~~~s,Ql~~~~~~io~? 
aximal VO, < 14 ml/kg per mint at4 major II 
of the pat;cm’z. daily activities 
Recurrent unstable ischemia not amenable to bypass 
surgery or an 
~~~stab~~~ty of an&e f~~ct~o~ not due to 
patient nonco with re en of weight monltor- 
ing, flexib?e use of diuretic drugs and sa@ restriction 
C14rrmt Statirs of l+ioety 
The current means of recipient categorization in the U.S. 
includes an estimation of the recipient’s severity of illness 
and determination of ABO blood type, body size and length 
of time on the waiting list. Because of the expaa?ding number 
of recipients, the primary determinants of 0 
hz~ come to be severit y of i!?ness and time 
The physically small adult recipient or 
blocd groups will usually be on a sm 
but donor availability is also limited for these patients. 
Current prioritization systems i Me a local a~~o~atio~ 
system and a national listing, bot which are s~j~erv~s~d 
by UNOS. Local organ procurement organizations will 
allocate the donated organs to all locally listed recipients 
according to UNQS-approved allocation policies before 
I’8 MliDCiE ET A?_. 
TASK FORCE 3 
JACC Vd. 22, No. 1 
9uiy 1993:L64 
Table 4 Currealt Recipient Status Criteria of the United Network 
r^oi rgan Sharing (UIkXj 
SiatUS 1 
Patients who require cardiac and/or pulmonary assistance with one or 
more of the following devices: 
(i) Total artificial heart 
(ii) Left and/or right ventricular assist systems 
(iii) Intra-aortic kiloon pump 
(iv) Ventilator 
Or, patients meeting BOTH of the fnl!n~ing criteria: 
(i) Patient in an intensive care unit and 
(ii) Patient re(~ki~b inOtroF.l nip agents to maintain adequate cardiac 
OUtQUt 
Or, patients less than six months old 
status II 
All other waiting patients who do sot meet the Status li criteria 
-?JNOS Executive Order, June 24. W92. 
these organs become available for more general distribution 
according to UNQS national prioritization rules. Highest 
priority is given to those patients whose condition is consid- 
ered urgent, or status I, a classification limited strictly to 
patients in an intensive care unit who are dependent on 
intravenously administered inotropic agents or on a mechan- 
ical support device. All other patients, whether in or out of 
the hospital, are considered tobe in status 11 (Tabie 41, The 
general rationale for such a simplified two-status system was 
an attempt to instill some degree of accountability for each 
transplant institution, the assumption being that intensive 
care units would not be improperly utilized to modify a 
patient’; priority. Many organ procurement organizations 
have successfully applied for loco1 allocation “variance: ,”
that allow f,>r an intermediate status, characterized in most 
cases by heart failure that require; hospitalization without 
intensive care, low dose inotropic support uot admini!kred 
in an intensive care unit setting, unstable angina or persistent 
life-threatening arrhythmias. 
The patient’s time on the waiting list is the second most 
important factor in allocation, and begins with the date the 
patier?t is entered on the transplant waiting list. According to 
UNOS guidelines, waiting time is not accrued on a national 
basis when patients are temporarily Iisted in an inactive 
status, but local recipients may return to their original 
listing date if ihey have been temporarily classified as 
inactivated because of intercurrent comp!ications. Although 
there is a current means of classifying a patient with inter- 
current illness as inactivated, there is no systematic and 
uniformly applied means of so classifying the patient whose 
condition stabilizes on medical therapy, without jeopardiz- 
ing their previously accrued waiting time. FinaIIy, logistic 
issues of transportation have been addressed by UNOS, 
(Table 5! but because of the number of transplant programs 
and large regional waiting lists, these logistic onsiderations 
are of minimal importance for most critically ill candidates. 
There continues to be controversy as to whether organs 
shou!d be distributed according to program or patient Ioca- 
tion. 
TIIese is widespread comxm-3 ixer ~~e~~ity in ide~iify~a~ 
patients who “urgently” require transplanterion. FrGgrarns 
with underutilized or strategicallly ea~arg~d intensive care 
unit facilities are more likely to board patients with severe 
heart failure on inotropic support and allow earIier tra 
tation. Nursing protocols at some i~stit~t~oos may 
!sw dose inotropic agents to be administered in an intensave 
care unit setting, enhancing a patient’s priority without 
attendant c~a~~~ in cIi~~ca$ status. I other cases, ~atieats 
legitimately appearing to be in critical condition may sh 
improvement over time and no longer need urgent transpl 
tation but they continue to be listed at a big 
practices may penalize ~atic~~ts who receive d~~i~cat re 
that leads to hospital discharge, prevents future bospitaliza- 
tions and may also lead to better esults after transplanta- 
tion. 
Priority for criticalIy ill patients has also been cba~Ieaged 
because such patients have a higher overall moita&y rate 
after transpkntation a d currently have the highest priority. 
Although some individual centers have reported e~~ivaleat 
survival data fgr crikally ill and ool~cr~tica~Iy ill patients, the 
International Registry demonstrates anoperative mortality 
rate of 14% for critically ill patients compared with 6% for 
those in stable condition. If the candidate popuiation 1s 
considered as a whole. survival clfrer tra~s~Iantatior~ is 
maximized by ~e~~~~i~g tra~~s~I~ntation only ia the bealth- 
ier outpdtients. However, survival for the entire recipient 
pool should be maximized by performing trans~!antatioo 
first in the patients most IikeIy to die without ransplantation, 
as shown in a computer model constructed using cm-rent 
data for waiting list death, deterioration a d posttransplan- 
tation mortality for regular and critical status candidates 
(43. In this model the benefit of giving priority to the sicker 
patients would be preserved unless their posttransplant 
mortality rate approached 50%. It is important to recognize 
that the current priority system does maximize survival for 
critical’ly ill patients initially listed as outp??!?icnts, becxase 
the condition of some of these will deteriorate othe point of 
requiring urgent trimsplani,ation as class I priority. 
Priority for outpatients ofsimilar size and blood grouping 
is currentiy based solely on waiting list time. The kmediate 
impact of this policy is to S&X: patients -who have demon- 
strated survival without transphintation. A subgroup of 
outpatients who can survive without ransplantation for6 
months (the current average waiting time) Silas a.n expected 
survival rate of 53% over the next I2 months, which is 
comparable tothat after transplantation. Within the next 5 
years the cumulative effect of our current listing and priority 
policy is that the number of outpatient candidates will 
expand to ~4,000 whereas hearts will go onIy to patients 
whose condition has so deteriorated that they are in-hospital 
candidates for urgent ransplantation. 
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2. Wean-iung combination patieni; ABC identical 
3. heart-lung ~ombi~lio~ palient. ABO com~~~ti% 
Zone B 
4. $k!%ls i htdri iWit!!fi$ iuiigj pittlen 
&y;y !? ..“.J p .., ,.#,Ld ._ 
5. Heart-lung combination patient, ABO idrntica! 
6. Heart-lung combination patient, Al30 compatibie 
Serothy A!hatiott: 
Zotle A 
9. Status 2 heart (without lung) patient. ABO identical 
S. Status 2 heart (without lungt patient. ADO compatible 
ZCiii D 
9. Status 2 heart (without lung) patient. AEN identicai 
I 
I I. Status I heart (witho;Et lung) patient 
12. Status Z heart [without lung) patient, ABO identical 
13. Status 2 hcai; ('*iiilout i ng) patrent, ABO compzibie 
The drst2nr.e of the recipient hospital from the donor hospital wilt also be uset to p-ioritire the recipien! list for hearts. lungs, and heart-?ung combmatron not 
used by the tocat @PO. Three zone! ivill be defined by concentric circles of liHt and I .OoU miie radii with the donor hospirat a5 the center. Zone A wilt 
extend to Mu miles. Zone !? is defined between SOtt and P.rNIo mites. Zone C is defined as beyond 1.000 miles. 
----- __.. _-_ -.. --~ 
TWOS Executive Or&r. June 24, 1992. OPO = organ procurement organization. 
‘l’wenty-Eve years ago, the 5th Bethesda Conference 
preJicted the dilemmas of recipient evalu 
zation that arc now ermrgkg. This 24tb 
ence accepts its ~~ofess~~:~a~ es~o~sjb~~~ty to provide direc- 
tion toward maximizing the life-savin.g potential of heart 
t~aosp~~~tat~on. We recommend that the following guide- 
line’, be adopted in the care of all patients considered for 
heart ~a~s~~a~tat~o~: 
1. The evaluaiion of end-stage heart disease and sekctiors 
of patients for potential heart ~~~s~~a~tat~o~ should be done 
by a ~“~tidi~~i~!~~a~~ Seam nitb ~~~~~o~~iate expertise in 
management of congestive hcai-t faihrre and high risk surgi- 
cal intervention as we/P 85 tra,nsplan&aticn. Eariiy evaluation 
by such a team should be encouraged, even if imminent 
transplaetation is ot anticipated. 
2. The indication for transg”lantatioo is e&stage heart 
dtsease including beart failure, refractory ischenia and ar- 
rhy?hta;lias, which kve led to usramqtablc 
surviva”, and mxceptable djsab~~~ty eveaafter csreful coi:- 
sideration si ait other medicai and surgical therapy. 
3. The indication for heart trmspkmtation i  pe&mic 
pa’.ie:its includes end-stage hea.pi failure an 
sions not amenable tosurgical repair. 
4. The. initial evaluation ~roce~~~e for the potential 
transplant candidate should provide ach patient with a well 
defined grojlle ekar fmompasses recognized ~~~~~o~~t~c vati- 
abks that predict survival but defines asingle point in time in 
what is clearly a dymipiic process. It is c:sx%fid i~ c~n?i8?- 
ua3y address reversible factors of deca 
j. Potenaial recipients should be ria 
All 
ters s~~~~~~ s~~e~ th se objective c~‘:” :ria i 
active or inactive status of potential recr,Gent 
6. All waiting candidates s ould be reevakated atregular 
mtervais of r3 months and undergo hma! reevaluation at 
least yearly whether they are on the irmsqlant list or iniriaily 
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considered not 13 need transpianiation. The j-month reeval- 
uation should include at a minimum a detailed history. 
physics! examination a d exercise test with peak VO-, mea- 
surement; yearly r~cvaittatioas should include a complete 
reevaluation, i c!uding right heart catheterization i@ mea- 
sure pulmi;nary vascrilar resistance. 
7, Patients and their referring physicians shstild be in- 
formed at the time of evaluation that iisti~g is a dyrramis 
state from which a given candidaie may he removed and 
returned as his condition changes. Patients hould be clas- 
sified as on inactive status if their condition improves. 
8. Discussions with UNOS should be encouraged to 
explore means of systematically “de-listing“ patients who 
become ciinical!i stable withoui jeopXiliZil3g their previ- 
nUs!y accrued w&iag time should their cor,dition deierb- 
rate. 
8. Collection itnd application of pro;pZiile m:!ticenter 
data on risks before and after transplantation shouid ise 
encouraged to ensure that this life-saving resource is opti- 
mally UiiliZd. 
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Heart tr~~sp~a~tat~Q~ aEords a r,.., -=&r&able degree of reha- 
biiiiatior~ for paiienls with end-Stage heart faiiure and aI sf 
its attendant herdynamic abnormalities and functiona! 
limitzdions. in highly selected patients this silrgica! proce- 
dure is vastly superior 
. . ,. 
to other exlstmg rorsnS c!, ,,,,...p, -c *Lnra v in 
improving functional capacity and survival. Cardiac d- 
lografts, however, do {lot fufiction tot& normaily and 
exercise tdrra3ce In trar,spiant recipieiits is somewhat less 
than might be expected. It is important to understand the 
implications of the altered physiology of the denervated 
heart because of its re!aiion to exercise tolerance. physica! 
rehabilitation, postoperative coimplications dnd pharmaco- 
therapeutic intervention. 
Heart transplant recipients often ham severe psychoiogic 
djr;function caused by symptirms from their previous car- 
Tiie function d the orthotopically 
complicated interplay of ventricular lodding c 
trinsic myocardial contractile capability. circulati 
choiamine levels, denervation (with, in some cases, pa&! 
reinnervation), donor/recipient size relation, ~~~~~~~la~~ per- 
formance and atrial function. Table 1 summarizes many of 
the issues relevant to ffrnction of the transplantid heart. 
